Head-to-head · WeighScore
Embody vs Nu Image Medical
The verdict
Embody takes it — 76.5/100 to 67.3/100.
Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Embody | Nu Image Medical |
|---|---|---|
| WeighScore | 76.5/100 | 67.3/100 |
| Grade | C | C |
| Site position | #52 | #185 |
| Semaglutide | $79/mo (all doses, promotional rate, compounded) | From $99/mo injection on 12-month supply; RDT from $269/mo |
| Tirzepatide | $129/mo (all doses, promotional rate, compounded) | From $289/mo injection; RDT from $314/mo |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Site position #52 · C
Strengths
- Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
- Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- Available in all 50 states with no insurance friction
- 24/7 unlimited clinician messaging and dose-adjustment support included
- Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Where it loses points
- The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
- Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- Pharmacy partners not publicly named — compounding source transparency is limited
- Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Site position #185 · C
Strengths
- Separate public product pages identify both medications and oral formats
- Publishes injection and tablet starting rates
Where it loses points
- Lowest semaglutide injection rate requires a twelve-month supply
- Final charge, renewal and dose-specific terms need confirmation
- Compounded tablets are not FDA-approved brand-name pills
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.